Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC: updated analysis of the observational GioTag study

Written by M Hochmair, A Morabito, Desiree Hao et al.

GioTag was a global, observational study conducted across ten countries to assess the cumulative benefit of sequential EGFR TKIs in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). The latest Short Communication published by Future Oncology presents an updated analysis of the observational GioTag study.

Abstract

Aims: Overall survival (OS) and updated time-to-treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) NSCLC who received sequential afatinib/osimertinib in the real-world GioTag study.

Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. OS analysis was exploratory.

Results: Median OS was 41.3 months (90% CI: 36.8–46.3) overall and 45.7 months (90% CI: 45.3–51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80% and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8–30.3).

Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive NSCLC, especially in patients with Del19-positive tumors.

View the full paper

Overall survival in patients treated with sequential afatinib and osimertinib therapy.